HIGHLIGHTS
SUMMARY
Numerous studies reported that TRPM2 was widely expressed in various tumor cells including neuroblastoma, gastric cancer, pancreatic cancer, acute myeloid leukemia, and prostate cancer. Here the authors further determined that TRPM2-S was the "real" prognostic biomarker in RPLS by IHC staining with antibodies targeted on different sites of TRPM2. The authors also constructed RPLS cell lines (94T778 and SW872) stably expressing TRPM2-S to reveal the function of TRPM2-S splice variant and its bipolar function in RPLS via increasing ROS levels. After being treated with 3% endogenous catalase blocker (ZSBIO, PV-6000 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.